Willow Biosciences Stock Today
| WLLW Stock | CAD 0.09 0.01 6.25% |
Performance0 of 100
| Odds Of DistressOver 84
|
Willow Biosciences is selling at 0.085 as of the 2nd of December 2024; that is 6.25 percent increase since the beginning of the trading day. The stock's open price was 0.08. Willow Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Willow Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of December 2022 and ending today, the 2nd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. Willow Biosciences Inc. was incorporated in 1981 and is headquartered in Calgary, Canada. The company has 144.2 M outstanding shares of which 120.38 K shares are at this time shorted by private and institutional investors with about 0.09 days to cover all short positions. More on Willow Biosciences
Moving together with Willow Stock
Moving against Willow Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Willow Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Willow Biosciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Willow Biosciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Director President | Chris Savile | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
Willow Biosciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Willow Biosciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsWillow Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Willow Biosciences' financial leverage. It provides some insight into what part of Willow Biosciences' total assets is financed by creditors.
| |||||
Willow Biosciences (WLLW) is traded on Toronto Exchange in Canada and employs 19 people. Willow Biosciences is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.26 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Willow Biosciences's market, we take the total number of its shares issued and multiply it by Willow Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Willow Biosciences operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 144.2 M outstanding shares of which 120.38 K shares are at this time shorted by private and institutional investors with about 0.09 days to cover all short positions.
Willow Biosciences has accumulated about 11.01 M in cash with (10.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Willow Biosciences Probability Of Bankruptcy
Ownership AllocationWillow Biosciences retains a total of 144.2 Million outstanding shares. Willow Biosciences owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Willow Ownership Details
Willow Biosciences Risk Profiles
Although Willow Biosciences' alpha and beta are two of the key measurements used to evaluate Willow Biosciences' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.55 | |||
| Standard Deviation | 5.29 | |||
| Variance | 27.94 | |||
| Risk Adjusted Performance | 0.0043 |
Willow Stock Against Markets
| WLLW | 6.25 |
| Compare Correlations |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Willow Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Willow Biosciences Corporate Management
Elected by the shareholders, the Willow Biosciences' board of directors comprises two types of representatives: Willow Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Willow. The board's role is to monitor Willow Biosciences' management team and ensure that shareholders' interests are well served. Willow Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Willow Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sanjib LLB | Corporate Secretary | Profile | |
| Simon Hickling | Sr Devel | Profile | |
| Peter SeuferWasserthal | CEO Pres | Profile | |
| Troy Talkkari | Vice Development | Profile | |
| Travis Doupe | Chief Officer | Profile | |
| Trish Choudhary | Senior Development | Profile |
Other Information on Investing in Willow Stock
Willow Biosciences financial ratios help investors to determine whether Willow Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Willow with respect to the benefits of owning Willow Biosciences security.